4D pharma plc (LBPS) News
Filter LBPS News Items
LBPS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LBPS News Highlights
- LBPS's 30 day story count now stands at 6.
- Over the past 27 days, the trend for LBPS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DRUG, AIM and STAR are the most mentioned tickers in articles about LBPS.
Latest LBPS News From Around the Web
Below are the latest news stories about 4D Pharma PLC that investors may wish to consider to help them evaluate LBPS as an investment opportunity.
4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines SummitLEEDS, England, February 23, 2022--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that Duncan Peyton, Chief Executive Officer, and Alex Stevenson, Chief Scientific Officer of 4D pharma, will participate in a fireside chat at the Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022 at 9:00 a.m. ET (2:00 p.m. GMT). |
4D Pharma To Test Its Single-Strain Live Biotherapeutics In Parkinson's DiseaseThe FDA has signed off 4D pharma plc's (NASDAQ: LBPS) investigational new drug (IND) applications for two Live Biotherapeutics (LBPs), MRx0005 and MRx0029, for Parkinson's disease. The Company expects to initiate a first-in-human Phase I clinical trial in people with Parkinson's disease in mid-2022. "We believe MRx0005 and MRx0029 are the first ever Live Biotherapeutic products for Parkinson's to enter the clinic," said Dr. Alex Stevenson, Chief Scientific Officer, 4D pharma. "Current treatments |
4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson’s DiseaseLEEDS, England, February 22, 2022--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that the U.S. Food and Drug Administration (FDA) has cleared investigational new drug (IND) applications for two Live Biotherapeutics (LBPs), MRx0005 and MRx0029, for the treatment of Parkinson’s disease. The Company expects to initiate a first-in-human Phase I clinic |
4D Pharma restates first-half earnings due to accounting changeThe London- and U.S.-listed pharmaceutical company said the warrants and units should be recorded as derivative liabilities and not equity instruments under both IFRS and U.S. GAAP accounting standards. |
Ladenburg Thalmann & Co. Thinks 4d Pharma’s Stock is Going to RecoverLadenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on 4d Pharma (LBPS – Research Report) today and set a price target of $35.00. The company's shares closed last Thursday at $4.03, close to its 52-week low of $3.55. According to TipRanks.com, Higgins is a 3-star analyst with an average return of 3.5% and a 29.8% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Armata Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for 4d Pharma with a $35.00 average price target. |
4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of AsthmaLEEDS, England, January 27, 2022--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces additional clinical data from Part A of its Phase I/II trial of MRx-4DP0004, an orally-delivered single strain Live Biotherapeutic being developed for the treatment of asthma. The Company previously reported topline safety and efficacy data from Part A, and today annou |
How Much Of 4D pharma plc (LON:DDDD) Do Insiders Own?Every investor in 4D pharma plc ( LON:DDDD ) should be aware of the most powerful shareholder groups. Insiders often... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayGood morning, investor! |
Ladenburg Thalmann & Co. Maintains a Buy Rating on 4d Pharma (LBPS)In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on 4d Pharma (LBPS – Research Report), with a price target of $35.00. The company's shares closed last Wednesday at $4.35, close to its 52-week low of $4.25. According to TipRanks.com, Higgins is a 3-star analyst with an average return of 4.8% and a 31.6% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Armata Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for 4d Pharma with a $35.00 average price target. |
4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape and Review of Positive Topline Results from Part A of Phase I/II Trial of MRx-4DP0004LEEDS, England, January 20, 2022--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that it will host a virtual Key Opinion Leader (KOL) event to review previously disclosed positive topline results from Part A of its Phase I/II trial of MRx-4DP0004 for the treatment of asthma and to discuss the asthma treatment landscape. The event will take place on |